Etoricoxib in the Treatment of Osteoarthritis (MK-0663-007)

• Status: Completed
• Trial end date: 2002-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety and efficacy of etoricoxib in the treatment of osteoarthritis of the knee.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Diclofenac; Etoricoxib

Criteria

Inclusion Criteria:

• At least 40 years of age with a clinical diagnosis of Osteoarthritis (OA)of the knee for 6 months prior to study entry (ARA class I, II, or III).

• Positive therapeutic effect from prior NSAID therapy.

• Worsening of symptoms upon withdrawal of prior treatment.

• With the exception of OA, in otherwise good health

Exclusion Criteria:

• Weight no more than 280 pounds (male or female).

• Recent, sustained use of gastroprotective agents.

• History of arthroscopy of the affected knee within 6 months prior to study entry.

• History of acute ligamentous or meniscal injury of the study joint within the previous 2 years.